|
|
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Research
General Research
- Non-Nucleoside Reverse Transcriptase Inhibitors in Development (October 11, 2009)
To read PDF, click here
From AIDS InfoNet
- When HIV Regimens Fail, Resistance Risk Appears Higher on NNRTIs Than Protease Inhibitors (October 3, 2008)
From aidsmap.com
- Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From The Body PRO
- NNRTIs: The Next Generation Approaches (Part II) (December 14, 2006)
From The Body PRO
- People With History of Depression More Likely to Stop Efavirenz Due to Mental Health Problems (July 26, 2006)
From aidsmap.com
- HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO
- HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
Efavirenz (Sustiva, Stocrin)
- Sustiva + Ginkgo: Possible Recipe for Resistance, Doctors Report (May 21, 2009)
From aidsmap.com
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (November/December 2008)
In HIV Treatment Bulletin, from HIV i-Base
- Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
In aidsmap.com
- Sustiva Study Finds Ethnicity, Quality of Life Predict Treatment Outcomes (April 1, 2008)
From Project Inform
- High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSMeds.com
- Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline NNRTI Resistance and Virologic Failure in Treatment-Naive Patients on Efavirenz: An Interview With Daniel Kuritzkes, M.D. (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz-Based Regimens Best Lopinavir/Ritonavir Regimens in Head-to-Head Trial (August 17, 2006)
In XVI International AIDS Conference
- ACTG 384 Substudy: DEXA Outcomes in Antiretroviral-Naive Patients Randomized to Efavirenz or Nelfinavir or Both Plus Nucleoside Backbone (August 16, 2006)
In XVI International AIDS Conference
- Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
- HIV JournalView: Efavirenz Has No Significant, Lasting Impact on Neuropsychological Performance (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Nevirapine (Viramune)
- Nevirapine Matches Atazanavir/Ritonavir in 48-Week Study (July 29, 2009)
Nevirapine has equivalent efficacy to atazanavir/ritonavir when combined with tenofovir and emtricitabine in treatment-naive patients, results from the ARTEN study show.
From aidsmap.com
- Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests (July 20, 2009)
Patients taking nevirapine may have a lower risk of developing cardiovascular disease than those taking ritonavir-boosted atazanavir, according to a 569-patient study by European researchers. The study found that although nevirapine's efficacy was non-inferior to that of atazanavir, nevirapine appeared to have a more favorable lipid profile.
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSMeds.com
- Nevirapine-Associated Toxicity Less Frequent in Non-Naive Patients (August 17, 2006)
In XVI International AIDS Conference
- Hepatotoxicity in IDUs and Non-IDUs Receiving Nevirapine-Based HAART (August 16, 2006)
In XVI International AIDS Conference
- Nevirapine Resistance May Persist in Some Pregnant Women, Study Finds (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- In Uganda, Three-NRTI Regimen Including Abacavir Is Better Tolerated Than Nevirapine-Based Regimen (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
|
Advertisement
|
E-Mail
Glossary
Share